Capsule Summary Slidesets

Share

Program Content

Activities

  • Pembro + Lenvatinib + CT for GEC
    LEAP-015: Phase III Safety Run-in Data With Pembrolizumab + Lenvatinib + Chemotherapy for Advanced Gastroesophageal Cancer
    Conference Coverage
    Slideset
    Congratulations: You achieved a completion on 04/09/2022

    Released: January 25, 2023

    Expires: January 24, 2024

    View Activity
  • Zolbetuximab for CLDN18.2+ GEC
    SPOTLIGHT: Phase III Study of First-line Zolbetuximab + mFOLFOX6 for Advanced CLDN18.2+/HER2- Gastric/Gastroesophageal Junction Adenocarcinoma
    Conference Coverage
    Slideset
    Congratulations: You achieved a completion on 04/09/2022

    Released: January 25, 2023

    Expires: January 24, 2024

    View Activity
  • Nab-Paclitaxel + Gem/Cis for BTCs
    SWOG 1815: Phase III Trial of First-line Gemcitabine/Cisplatin ± Nab-Paclitaxel for Advanced Biliary Tract Cancers
    Conference Coverage
    Slideset
    Congratulations: You achieved a completion on 04/09/2022

    Released: January 26, 2023

    Expires: January 25, 2024

    View Activity
  • NALIRIFOX for mPDAC
    NAPOLI 3: Phase III Trial of First-line NALIRIFOX vs Nab-Paclitaxel + Gemcitabine for Metastatic Pancreatic Adenocarcinoma
    Conference Coverage
    Slideset
    Congratulations: You achieved a completion on 04/09/2022

    Released: January 30, 2023

    Expires: January 29, 2024

    View Activity
  • TAS-102 ± Bev for Refractory mCRC
    SUNLIGHT: Phase III Trial of TAS-102 With or Without Bevacizumab for Third-line Treatment of Refractory Metastatic Colorectal Cancer
    Conference Coverage
    Slideset
    Congratulations: You achieved a completion on 04/09/2022

    Released: January 30, 2023

    Expires: January 29, 2024

    View Activity
  • HER2 Scoring Systems in mCRC
    Concordance Analysis of Gastric and Breast Cancer HER2 Scoring Systems for mCRC From the MOUNTAINEER Phase II Trial
    Conference Coverage
    Slideset
    Congratulations: You achieved a completion on 04/09/2022

    Released: January 30, 2023

    Expires: January 29, 2024

    View Activity
  • Pemigatinib in mCRC
    Phase II Study of the FGFR Inhibitor Pemigatinib for Previously Treated Metastatic CRC With FGF/FGFR Alterations
    Conference Coverage
    Slideset
    Congratulations: You achieved a completion on 04/09/2022

    Released: January 30, 2023

    Expires: January 29, 2024

    View Activity
  • CheckMate 649 Update
    CheckMate 649 Update: Phase III Study of First-line Nivolumab + CT vs CT for Advanced Gastric/GEJ Cancer and Esophageal Adenocarcinoma
    Conference Coverage
    Slideset
    Congratulations: You achieved a completion on 04/09/2022

    Released: January 30, 2023

    Expires: January 29, 2024

    View Activity
  • CheckMate 648 Update
    CheckMate 648 Update: Phase III Study of First-line Nivolumab + CT vs Nivolumab + Ipilimumab vs CT for Advanced Esophageal Squamous Cell Carcinoma
    Conference Coverage
    Slideset
    Congratulations: You achieved a completion on 04/09/2022

    Released: February 02, 2023

    Expires: February 01, 2024

    View Activity

Provided by

ProCE Banner

Supporters

Bristol Myers Squibb

Incyte Corporation

Merck Sharp & Dohme Corp.

Seagen Inc.